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osting by EAbstract Purpose: Furosemide is a commonly used diuretic which is used in the treatment of
edema, congestive heart failure, hypertension and renal failure. Its absorption exhibits inter- and
intra-subject variability that can be attributed to many factors including the intestinal efﬂux pumps
such as the P-glycoprotein (P-gp). This study was done due to the great disagreement between what
is published in the literature regarding the inﬂuence of P-gp on furosemide and at the same time due
to the importance of this drug in the treatment of different conditions as described above. In addi-
tion, an investigation of the effect of two of the commonly used pharmaceutical excipients
(hydroxypropyl b-cyclodextrin [HPbCD] and Tween 80) and also a P-gp inhibitor (verapamil
hydrochloride) on the intestinal absorption of this drug were also done.
Methods: The study utilized the everted intestinal sacs technique to investigate both the effect of
the efﬂux transporter (P-gp) on furosemide absorption and also the effect of the chosen excipients.
Results: The absorption of furosemide was signiﬁcantly inﬂuenced by the P-gp as conﬁrmed by the
everted vis the non-everted sacs together with the verapamil study in which the transport of furo-
semide was inhibited by verapamil. In addition, Tween 80 was also shown to inhibit the P-gp pump
whereas the HPbCD did not signiﬁcantly inﬂuence the efﬂux of furosemide in this study.
Conclusions: P-glycoprotein and some of the used excipients in the formulation play a very impor-
tant role in the transport of furosemide and other drugs. Thus excipients that affect the activity of
P-gp should be avoided when formulating drugs that are substrate for the P-gp or other efﬂux
pumps.
ª 2010 King Saud University. All rights reserved.ity. All rights reserved. Peer-
d University.
lsevier1. Introduction
Furosemide is a loop diuretic which is used in the treatment of
edema, congestive heart failure and hypertension. It is also
used for the treatment of both acute and chronic renal failure
(Berko et al., 2003). Furosemide is a weak acid (pKa = 3.9)
that is incompletely absorbed from the gastrointestinal tract
after oral administration and it is available in the form of both
98 A.M. Al-Mohizeaoral and parenteral formulations (Berko et al., 2003). It’s
absorption exhibit inter- and intra-subject variability. This var-
iability can be attributed to many factors such as pH, food in-
take, drug metabolizing enzymes and efﬂux pumps in the
intestine, dosage form administered, etc. (Chungi et al., 1979;
Hammarlund et al., 1984). The inﬂuence of intestinal efﬂux
transporters such as P-gp (P-glycoprotein), MRP (multidrug
resistance protein), etc. on furosemide absorption is controver-
sial. Some studies have reported a negative impact of these
transporters on its absorption (Polli et al., 2001; Verma
et al., 2004; Verma and Panchagnula, 2005a,b; Bansal et al.,
2007) whereas other studies have reported positive effect for
the P-gp on its intestinal absorption (Pade and Stavchansky,
1998; Rege et al., 2001; Pole, 2008).
Accordingly, the objectives of this paper were to study the
intestinal absorption of furosemide and determine the exact
inﬂuence of the intestinal efﬂux transporter (P-gp) on its intes-
tinal absorption. Also, to investigate the effect of two of the
commonly used pharmaceutical excipients hydroxypropyl b-
cyclodextrin (HPbCD) and Tween 80 on the intestinal absorp-
tion and transport of this drug. This is based on what was
shown in the literatures that some pharmaceutical excipients
have either positive or negative inﬂuence on the absorption
and transport of some drugs (Lo, 2003; Wagner et al., 2001).
Several techniques have been reported in the literature to
investigate the effect of intestinal efﬂux pumps on drug trans-
port. These techniques include the in situ intestinal perfusion
(Verma et al., 2004; Verma and Panchagnula, 2005a,b), the
Caco-2 cell model (Bansal et al., 2007; Pade and Stavchansky,
1998; Rege et al., 2001) and the everted intestinal sacs model
(Barthe et al., 1998). This study employed rat everted intestinal
sacs and compared the permeation of the drug through everted
versus non-everted sacs. In addition, the effect of co-incuba-
tion of furosemide and verapamil, a well known P-gp inhibitor
was studied.
2. Materials and methods
The animal experiments and the study protocol were approved
by the ethics committee of King Saud University.
2.1. Materials
Furosemide was purchased from Co. Pharmaceutica Milanese,
SPA (Italy). Hydroxypropyl b-cyclodextrin, verapamil hydro-
chloride and carbamazepine were purchased from Sigma
Chemicals Co. (USA). Acetonitrile (HPLC grade) was pur-
chased from BDH (England).
2.2. Preparation of intestinal sacs
Male Sprague–Dawley rats (250–300 g) were obtained from
the Animal Care Center at King Saud University. Rats were
given free access to food and water and on the night before
the experiment the animals were fasted with free access to
water. At the day of experiments, the rats were anesthetized
by ether inhalation. After veriﬁcation of loss of the pain reﬂex,
a midline abdominal incision of 4–5 cm was made and the jeju-
num was separated and washed with an ice cold oxygenated
Krebs solution (pH 6.5) containing 7 g/l sodium chloride,
0.34 g/l potassium chloride, 1.8 g/l glucose, 0.251 g/l disodium
hydrogen phosphate, 0.207 g/l sodium dihydrogen phosphateand 46.8 mg/l magnesium chloride. The washed intestine was
then divided into approximately 6 cm long sacs. Two sacs were
taken from each rat, one of which was gently everted over a
glass rod and the other was left non-everted. The sacs were tied
from one end using braided suture silk, weighted, ﬁlled with
the drug solution from the other end, and weighted again.
2.3. Determination of drug transport across the rat intestine
The study investigated the drug transport across everted and
non-everted intestinal sacs and monitored drug transfer in
presence and absence of verapamil hydrochloride. This design
allowed the investigation of the inﬂuence of P-gp on the
absorption and transport by two methods. The ﬁrst method in-
volved the comparison of the permeation of the drug through
everted and non-everted sacs and the second method compared
drug permeation in presence and absence of the P-gp inhibitor
(verapamil hydrochloride).
The sacs were tied from one end, loaded with 1 ml drug solu-
tion (10 lg/ml in oxygenated Krebs solution) in presence or ab-
sence of verapamil hydrochloride (200 lg/ml) and then tied
from the other end. The sacs were immersed in a 15 ml-size test
tubes containing 10 ml of Krebs solution maintained at 37 C
and continuously bubbled with oxygen. Samples from the out-
side solution were taken at regular intervals for 60 min and the
drug content in each sample was determined by HPLC.
2.4. Effect of HPbCD and Tween 80 on furosemide transport
across the rat intestine
The intestinal transport of furosemide was monitored in pres-
ence of either Tween 80 (3 mg/ml) or HPbCD (1:1 ratio with
the drug solution) together with the drug solutions (1 ml con-
taining 10 lg of the drug). The mixture (drug + Tween 80 or
drug + HPbCD) was loaded into the intestinal sacs and the
experiment was conducted as described in the above section.
2.5. Chromatography
The study utilized a high pressure liquid chromatograph
(HPLC) from Jasco (Japan) equipped with quaternary pump,
a variable wavelength detector (UV/vis detector) and an auto-
matic sampling system (auto-sampler). Separation was accom-
plished using a reversed phase C18, l-Bondapak column
15 cm · 3.9 mm (i.d.) from Waters (USA) with an average par-
ticle size of 10 lm. The mobile phase was a mixture of aceto-
nitrile and 20 mM phosphate buffer (35:65) running at a ﬂow
rate of 1 ml/min and Carbamazepine was used as an internal
standard. The column efﬂuent was monitored at 240 nm and
the chromatographic data analysis was performed with
Chrompass software (Jasco, Japan).
The samples were transferred to test tubes, spiked with the
internal standard in an amount sufﬁcient to produce a concen-
tration of 1 lg/ml. The tubes were vortex mixed for 2 min be-
fore loading into the HPLC vials. The injection volume was
30 ll.
2.6. Calculation of the apparent permeability
The apparent permeability coefﬁcient (Papp) was calculated
from the cumulative amount permeated versus time proﬁle
according the following equation:
Inﬂuence of intestinal efﬂux pumps on the absorption and transport of furosemide 99Papp ¼ dQ=dt  1=AC0
where dQ/dt is the steady state rate of drug appearance in the
receptor, A is the surface area of the intestinal sac and C0 is the
initial concentration of the drug in the sac.
The Papp through the non-everted sac was taken as a mea-
sure for the transfer from mucosal to serosal side (M-to-S) and
the Papp through the everted sac was taken as a measure for the
transfer from serosal to mucosal side (S-to-M).2.7. Statistical analysis
One way ANOVA followed by Tukey test was done to evalu-
ate the presence of signiﬁcant differences between different
groups at a p-value 6 0.05. This was carried out using Prism
Software version 3.02 (GraphPad Software Inc., San Diego,
CA).
3. Results
3.1. Intestinal transport and absorption of furosemide
The intestinal permeation parameters of furosemide were stud-
ied using the rat intestinal sacs model with the intestinal trans-
port of the drug being evaluated by two approaches. The ﬁrst
compared trans-intestinal transport from everted versus non-
everted intestinal sacs. The second approach investigated the
effect of P-gp inhibitor (verapamil hydrochloride) on the mem-
brane transport of furosemide. Fig. 1 shows the cumulative
amount of furosemide with time in presence and absence of
the P-gp inhibitor (verapamil hydrochloride). Table 1 shows
the intestinal permeability of furosemide through non-everted
and everted rat intestinal sacs in presence or absence of the P-
gp inhibitor (verapamil) or the excipients (Tween 80 or
HPbCD). It showed a very low permeability in the non-everted
rat intestinal sacs. This result reﬂects drug transfer from the
mucosal to serosal side (M-to-S) which mimics the in vivo con-
ditions. However, in the everted sacs, the drug showed signif-
icantly higher transport compared to its permeation through
the non-everted intestinal sac. This conﬁrms that the P-gp is in-
volved in the transport of the drug. The ratio of S-to-M to M-
to-S permeability was found to be 5.6 and this ﬁnding sug-
gested a possible role for the P-gp efﬂux pump in the intestinal
absorption of furosemide. A higher permeability in the S-to-M
direction than in the M-to-S direction has generally been0 20 40 60
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Figure 1 Time proﬁle of the transport of furosemide between the twconsidered as a prove that active transport (e.g., P-gp efﬂux)
is involved (Polli et al., 2001). In addition, the presence of
verapamil increased the M-to-S signiﬁcantly (Table 1). The ra-
tio of S-to-M to M-to-S permeability was decreased from 5.6
in absence of verapamil to 1.28 in presence of verapamil. This
ﬁnding further conﬁrms the effect of P-gp efﬂux mechanism on
the intestinal absorption.
3.2. Effect of excipients on the intestinal permeability to
furosemide
The study investigated the effect of Tween 80 and HPbCD as
two of the most commonly used pharmaceutical excipients on
the intestinal permeability and absorption of furosemide. Ta-
ble 1 shows the effects of excipients on the M-to-S and S-to-
M intestinal permeability of the drug. The apparent M-to-S
permeability of the drug which was obtained in presence of
the excipient was compared to that obtained in absence of
the excipient and the results are presented in Fig. 2. The calcu-
lated M-to-S transport indicated a permeation enhancing ef-
fect for Tween 80 but not for the HPbCD. This implied
signiﬁcant increase in the M-to-S permeability of the drug
compared to the control. The presence of HPbCD resulted in
marginal reduction in the S-to-M to M-to-S permeability ratio.
4. Discussion
4.1. Intestinal transport and absorption of furosemide
The intestinal permeation parameters of furosemide were stud-
ied in the presence and absence of verapamil using the rat
intestinal sacs model and the results of these investigations
are presented in Table 1. These results showed low permeabil-
ity in the non-everted rat intestinal sac. This result reﬂects drug
transfer from the mucosal to serosal side (M-to-S) which mim-
ics the in vivo conditions. Furosemide has been classiﬁed as
low permeable drug (Rege et al., 2001). In the everted rat intes-
tinal sacs, the drug showed signiﬁcantly higher transport (5.5-
folds) compared to its permeation through the non-everted
intestinal sac (Table 1). This conﬁrm that the P-gp is involved
and since the function of the P-gp pump is to pump back the
drug to the intestine after being absorbed, these results sug-
gested higher trans-intestinal permeation from the serosal to
the mucosal side (S-to-M). The ratio of S-to-M to M-to-S
permeability was found to be 5.6 and this ﬁnding suggested a80
M-to-S
S-to-M
M-to-S with verapamil
o sides of the intestinal scas in presence and absence of verapamil.
Table 1 Intestinal permeability of furosemide through non-everted and everted rat intestinal sacs in presence or absence of the P-gp
inhibitor verapamil, Tween 80 or hydroxypropyl b-cyclodextrin (HPbCD). Value are presented as mean (STD).
Applied solution Papp (cm/s) · 106
Non-everted sac (M-to-S) Everted sac (S-to-M) Ratio (S-to-M)/(M-to-S)
Drug solution 0.636 (0.093) 3.54 (0.67) 5.6
Drug + verapamil 4.81 (2.2) 6.17 (1.75) 1.28*
Drug + Tween 80 3.8 (1.1) 4.12 (0.8) 1.08*
Drug + HPbCD 0.703 (0.12) 3.22 (0.48) 4.58
M-to-S, the mucosal to serosal transport.
S-to-M, the serosal to mucosal transport.
* Signiﬁcantly different than control (drug solution alone).
Figure 2 Effect of verapamil and two excipients on the intestinal
permeability of furosemide (M-to-S). *Signiﬁcantly different than
control (drug solution alone).
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tion of furosemide. To further conﬁrm this ﬁnding the study
was extended to investigate the effect of verapamil Hydrochlo-
ride on the intestinal permeability of furosemide. The presence
of verapamil increased the M-to-S signiﬁcantly as compared to
the case with no verapamil (Table 1). This is due to the inhibi-
tion of the P-gp pump by the verapamil which will prevent the
drug from being pumped back to the mucosal side. Thus, more
drug will be accumulated in the serosal side (Fig. 1). The ratio
of S-to-M to M-to-S permeability was decreased from 5.6 in
absence of verapamil to 1.28 in presence of verapamil. This
ﬁnding further conﬁrms the effect of P-gp efﬂux mechanism
on the intestinal absorption. Similar ﬁndings were reported
for furosemide by other researchers (Verma and Panchagnula,
2005b; Pade and Stavchansky, 1998; Rege et al., 2001). Con-
trary to this, some researchers employed the drug as an intes-
tinal permeability marker which is not affected by intestinal
efﬂux (P-gp) (Verma et al., 2004; Verma and Panchagnula,
2005a,b; Bansal et al., 2007; Pole, 2008).
4.2. Effect of excipients on the intestinal permeability to
furosemide
The study investigated the effect of Tween 80 and HPbCD as
two of the most commonly used pharmaceutical excipients onthe intestinal permeability and absorption of furosemide. The
study evaluated the effects of excipients on the M-to-S and S-
to-M intestinal permeability of the drug. The results are pre-
sented in Table 1. The apparent M-to-S permeability of the
drug which was obtained in presence of the excipient was com-
pared to that obtained in absence of the excipient and the re-
sults are presented in Fig. 2. The results indicated a
permeation enhancing effect for Tween 80 but not for the
HPbCD. This implied signiﬁcant increase in the M-to-S per-
meability of the drug compared to the control. Tween 80
was able to reduce the ratio of S-to-M to M-to-S permeability
from 5.6 to 1.08. This effect provides an indication that Tween
80 is an inhibitor of the P-gp efﬂux pump. Similar ﬁndings
were reported by other researchers for Tween 80 with other
drugs (Zhang et al., 2003). The presence of HPbCD resulted
in marginal reduction in the S-to-M to M-to-S permeability ra-
tio. This suggests a minor (non-signiﬁcant) negative effect for
the HPbCD on the P-gp efﬂux mechanism.
5. Conclusion
The study conﬁrmed the effect of the P-gp efﬂux mechanism on
the intestinal transport and absorption of furosemide. This ef-
fect can be inhibited by verapamil hydrochloride or Tween 80.
The use of HPbCD did not signiﬁcantly inﬂuence the efﬂux of
furosemide using our model of everted sacs. The results of this
study stress on the importance of choosing the right excipients
during formulation of each drugs to avoid interfering with the
absorption and transport of the drugs being formulated.
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